Overview

Dermatology Drugs Market Overview:

FutureWise Market Research has instantiated a report that provides an intricate analysis of Dermatology Drugs Market trend that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Dermatology Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Dermatology Drugs Market:
• Novartis AG
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Merck & Co. Inc.
• Amgen Inc.
• AbbVie Inc.
• Eli Lilly and Company
• Galderma S.A.
• GlaxoSmithKline plc
• Mylan N.V.
• LEO Pharma A/S.
• Sanofi
• Ortho-Clinical
• Helena Laboratories
• Sklar Surgical Instruments
(Note: The list of the major players will be updated with the latest market scenario and trends)

Dermatology Drugs Market Segmentation:
By Treatment Type
• Topical corticosteroids
• Lower Limb Prosthetic
• Biologics
• Calcimeurin Inhibitors
• Antihistamines
• Hormone Therapy
• Others

By Drug Type
• Humira
• Remicade
• Otezla
• Stelara
• Enbrel
• Cosentyx
• Neoral
• Taltz
• Cubicin
• Canesten
• Zyvox
• Dupixent
• Protopic
• Valtrex
• Eucrisa
• Others

By Prescription Mode
• Prescription drugs
• OTC drugs

By Therapeutic Area
• Psoriasis
• Atopic dermatitis
• Acne

By Distribution Channel
• Direct
• Wholesale/retail
• Online

By End User
• Hospital
• Cosmetic Centers
• Clinics

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Dermatology Drugs Market By Treatment Type, By Drug Type, By Prescription Mode, By Therapeutic Area, By Distribution Channel, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexibility Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customisation offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
                2.1.1.1. Key Data from Secondary Sources
         2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Dermatology Drugs Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Dermatology Drugs Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Dermatology Drugs Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Dermatology Drugs Market, By Treatment Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Topical corticosteroids
   7.2. Retinoids
   7.3. Biologics
   7.4. Calcineurin Inhibitors
   7.5. Antihistamines
   7.6. Hormone Therapy
   7.7. Others

8. Dermatology Drugs Market, By Drug Type Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Humira
   8.2. Remicade
   8.3. Otezla
   8.4. Stelara
   8.5. Enbrel
   8.6. Cosentyx
   8.7. Neoral
   8.8. Taltz
   8.9. Cubicin
   8.10.Canesten
   8.11.Zyvox
   8.12.Dupixent
   8.13.Protopic
   8.14.Valtrex
   8.15.Eucrisa
   8.16.Others

9. Dermatology Drugs Market, By Prescription Mode Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Prescription drugs
   9.2. OTC drugs

10. Dermatology Drugs Market, By Therapeutic Area Historical Analysis and Forecast 2022-2028 (USD Million)  
    10.1. Psoriasis
    10.2. Atopic dermatitis
    10.3. Acne
    10.4. Rosacea
    10.5. Skin Cancer
    10.6. Scar
    10.7. Others
  
11. Dermatology Drugs Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)  
    11.1. Direct
    11.2. Wholesale/retail
    11.3. Online

12. Dermatology Drugs Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million)  
    12.1. Hospital
    12.2. Cosmetic Centers
    12.3. Clinics

13. North America Dermatology Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. U.S.A
          13.2.2. Canada
          13.2.3. Mexico
    13.3. Market Size (USD Million) Forecast for North America 2022-2028

14. Latin America Dermatology Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. Brazil
          14.2.2. Venezuela
          14.2.3. Argentina
          14.2.4. Rest of Latin America
    14.3. Market Size (USD Million) Forecast for Latin America 2022-2028

15. Europe Dermatology Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    15.1. Introduction
    15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          15.2.1. Germany
          15.2.2. U.K         
          15.2.3. France
          15.2.4. Italy
          15.2.5. Spain
          15.2.6. Russia
          15.2.7. Poland
          15.2.8. Rest of Europe
    15.3. Market Size (USD Million) Forecast for Europe 2022-2028

16. Asia Pacific Dermatology Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    16.1. Introduction
    16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          16.2.1. Japan
          16.2.2. China
          16.2.3. India
          16.2.4. Australia and New Zealand
          16.2.5. ASEAN
          16.2.6. Rest of Asia Pacific
    16.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

17. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    17.1. Introduction
    17.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          17.2.1. GCC
          17.2.2. Israel
          17.2.3. South Africa
          17.2.4. Rest of MEA
    17.3. Market Size (USD Million) Forecast for MEA 2022-2028

18. Market Share Analysis and Competitive Landscape   
    18.1. Global Landscape - Key Players, Revenue and Presence
    18.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    18.3. Global Emerging Companies
    18.4. North America - Market Share Analysis and Key Regional Players
    18.5. Europe - Market Share Analysis and Key Regional Players
    18.6. Asia Pacific - Market Share Analysis and Key Regional Players
    18.7. Global Key Player - Growth Matrix

19. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   19.1. Novartis AG
         19.1.1. Company Overview
         19.1.2. Product Portfolio
         19.1.3. SWOT Analysis
         19.1.4. Financial Overview
         19.1.5. Strategic Overview
   19.2.Bristol-Myers Squibb Company
         19.2.1. Company Overview
         19.2.2. Product Portfolio
         19.2.3. SWOT Analysis
         19.2.4. Financial Overview
         19.2.5. Strategic Overview
   19.3. Johnson & Johnson
         19.3.1. Company Overview
         19.3.2. Product Portfolio
         19.3.3. SWOT Analysis
         19.3.4. Financial Overview
         19.3.5. Strategic Overview
   19.4. Merck & Co. Inc.
         19.4.1. Company Overview
         19.4.2. Product Portfolio
         19.4.3. SWOT Analysis
         19.4.4. Financial Overview
         19.4.5. Strategic Overview
   19.5. Amgen Inc.
         19.5.1. Company Overview
         19.5.2. Product Portfolio
         19.5.3. SWOT Analysis
         19.5.4. Financial Overview
         19.5.5. Strategic Overview          
   19.6. AbbVie Inc.
         19.6.1. Company Overview
         19.6.2. Product Portfolio
         19.6.3. SWOT Analysis
         19.6.4. Financial Overview
         19.6.5. Strategic Overview      
   19.7. Eli Lilly and Company,
         19.7.1. Company Overview
         19.7.2. Product Portfolio
         19.7.3. SWOT Analysis
         19.7.4. Financial Overview
         19.7.5. Strategic Overview
   19.8. Galderma S.A.
         19.8.1. Company Overview
         19.8.2. Product Portfolio
         19.8.3. SWOT Analysis
         19.8.4. Financial Overview
         19.8.5. Strategic Overview
   19.9. GlaxoSmithKline plc
         19.9.1. Company Overview
         19.9.2. Product Portfolio
         19.9.3. SWOT Analysis
         19.9.4. Financial Overview
         19.9.5. Strategic Overview
   19.10.Mylan N.V.
         19.10.1. Company Overview
         19.10.2. Product Portfolio
         19.10.3. SWOT Analysis
         19.10.4. Financial Overview
         19.10.5. Strategic Overview
   19.11.LEO Pharma A/S.
         19.11.1. Company Overview
         19.11.2. Product Portfolio
         19.11.3. SWOT Analysis
         19.11.4. Financial Overview
         19.11.5. Strategic Overview
   19.12.Sanofi
         19.12.1. Company Overview
         19.12.2. Product Portfolio
         19.12.3. SWOT Analysis
         19.12.4. Financial Overview
         19.12.5. Strategic Overview
   19.13.Ortho-Clinical
         19.13.1. Company Overview
         19.13.2. Product Portfolio
         19.13.3. SWOT Analysis
         19.13.4. Financial Overview
         19.13.5. Strategic Overview
   19.14.Helena Laboratories
         19.14.1. Company Overview
         19.14.2. Product Portfolio
         19.14.3. SWOT Analysis
         19.14.4. Financial Overview
         19.14.5. Strategic Overview
   19.15.Sklar Surgical Instruments
         19.15.1. Company Overview
         19.15.2. Product Portfolio
         19.15.3. SWOT Analysis
         19.15.4. Financial Overview
         19.15.5. Strategic Overview

20. Pre and Post COVID-19 Impact
    20.1. Positive influence on the healthcare industry
    20.2. The financial disruption of the manufacturing sector
    20.3. Impact of COVID-19 on emerging companies
    20.4. Significant mandates in the healthcare regulations initiated by administrations
    20.5. The overall economic slowdown of the developing and developed nations

21. FutureWise SME Key Takeaway Points for Client

Tables

Figures